WILMINGTON – Evidera, a Maryland-based business unit of Pharmaceutical Product Development, is about to grow a bit larger.
The company says it is acquiring Medimix International, a global life science technology firm that works with clients to provide evidence about pharmaceutical, medical device and diagnostic development.
“The acquisition will enable Evidera to offer its customers enhanced technology solutions, real-world data and access to health care providers,” PPD and Evidera said in the announcement.
Financial terms were not disclosed.
Medimix draws on information and insight from some 2.2 million clinicians. Hematology and oncology are key areas of focus, according to the companies. It utilizies real-time cloud-based technology to provide real-time performance information based on client data.
“The addition of Medimix will expand our ability to help our clients plan for and generate the evidence needed to optimize the market access and commercial potential of their products,” said Karen Kaucic, president of Evidera. “We look forward to leveraging the capabilities and resources of Medimix to develop novel approaches to access and maximize the utility of real-world data.”
PPD is based in Wilmington and has a large operation in Research Triangle Park.
